Goldman Sachs
GYRE icon

Goldman Sachs’s Gyre Therapeutics GYRE Stock Holding History

Goldman Sachs’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-226
Closed -$737K – 6823
2013
Q4 		$737K Buy
226
+93
+70% +$367K ﹤0.01% 5001
2013
Q3 		$558K Buy
133
+46
+53% +$185K ﹤0.01% 5086
2013
Q2 		$293K Buy
+87
New +$331K ﹤0.01% 5335

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs's GYRE Position: Q1 2026 in Review

Goldman Sachs increased its Gyre Therapeutics (GYRE) stake by 135% in Q1 2026, buying an estimated $326K and bringing the position to 73,122 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #5582.

Goldman Sachs first reported a position in GYRE in Q2 2013 and has held it in 42 quarters since. The position peaked at $1.7M in Q4 2020. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Goldman Sachs held 73,122 shares of Gyre Therapeutics worth $510K as of Q1 2026.
  • Goldman Sachs bought 42,014 Gyre Therapeutics shares in Q1 2026, an estimated $326K.
  • Gyre Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5582 holding.
  • Goldman Sachs first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • Goldman Sachs's Gyre Therapeutics position peaked at $1.7M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.